RBC Capital Maintains Sector Perform on Sage Therapeutics, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Sage Therapeutics and raises the price target from $21 to $26.
February 15, 2024 | 3:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained a Sector Perform rating on Sage Therapeutics and increased the price target from $21 to $26.
The increase in price target by RBC Capital suggests a positive outlook on Sage Therapeutics' stock, potentially leading to a short-term increase in its stock price. The analyst's rating and target adjustment are direct indicators of expected performance, influencing investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100